toripalimab,disitamab vedotin
Coherus,Junshi Biosciences,rongchang pharma,seagen
['disitamab', 'toripalimab', ' vedo', 'vedo']
ph1/2 trial with disitamab vedotin (adc anti-her2) + toripalimab in muc. very promising orr of 73.2%, and responses observed irrespective of her2 expression. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer